Research Paper Volume 14, Issue 18 pp 7547—7567

Figure 6. The influence of distinct PPSscore on anti-PD-1/L1 immunotherapy. (A) Survival analyses for low and high PPSscore patient groups in the anti-PD-L1 immunotherapy cohort using Kaplan-Meier curves. (B) The percent weight of patients with clinical response to anti-PD-L1 immunotherapy in low or high PPSscore groups. SD/PD, stable disease/progressive disease; CR/PR, complete response/partial response. (C) The distribution of PPSscore in distinct anti-PD-L1 clinical response groups. (D) Survival analyses for low and high PPSscore patient groups in the anti-PD1 immunotherapy cohort using Kaplan-Meier curves. (E) The percent weight of patients with clinical response to PD-1 blockade immunotherapy in low or high PPSscore groups. (F) The correlation of PPSscore with clinical response to anti-PD-1 immunotherapy. Pt, patients. PD, green; PR, blue; CR, orange. (G) The distribution of PPSscore in distinct anti-PD-1 clinical response groups. (H) Differences in stroma-activated pathways between high and low PPSscore groups in anti-PD-L1 immunotherapy cohort. The upper and lower ends of the boxes represented the interquartile range of values. The lines in the boxes represented the median value. The asterisks represented the statistical P value (^***P < 0.001). (I) Survival analyses for patients receiving anti-PD-L1 immunotherapy classified by both PPSscore and neoantigen burden using Kaplan-Meier curves.